|Articles|April 10, 2008

NJEM Piece Critiques Biomedical HIV Trial Design (PDF)

A perspective piece from the New England Journal of Medicine calls for improvements in trial design for biomedical HIV treatments.

External Link - article-509590.pdf

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Long-Term APEX Trial Data Reinforce Tremfya’s Sustained Psoriatic Arthritis Control and Structural Protection

ByAndy Studna, Senior Editor

November 17th 2025

Choosing Nontraditional Digital Platforms for Patient Recruitment

ByChristian Bullock,Andy Studna, Senior Editor

November 17th 2025

ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care

ByAndy Studna, Senior Editor

November 17th 2025

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data

ByAndy Studna, Senior Editor

November 14th 2025

Proactive Planning is Key to Mitigating Study Rescue

ByAshley Daigneau

November 14th 2025

NJEM Piece Critiques Biomedical HIV Trial Design (PDF)

Newsletter

Related Content

Long-Term APEX Trial Data Reinforce Tremfya’s Sustained Psoriatic Arthritis Control and Structural Protection

Choosing Nontraditional Digital Platforms for Patient Recruitment

ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data

Proactive Planning is Key to Mitigating Study Rescue

Trending on Applied Clinical Trials Online

Long-Term APEX Trial Data Reinforce Tremfya’s Sustained Psoriatic Arthritis Control and Structural Protection

Choosing Nontraditional Digital Platforms for Patient Recruitment

ACT Brief: Smarter Study Planning, New AML Approval, and Biomarker Gaps in Cancer Care